In this issue... our top share tips for 2024, Aggressive Portfolio VIII in review and the launch of NEW Aggressive Portfolio IX, plus company features and market insight.
Company feature: Alliance Pharma
Shares in Alliance Pharma are currently standing at around the lowest point since 2015 and we believe that this is a good entry point for investors. The decline in the share price from 122p two years ago has been caused by a number of factors. These include a profit warning in 2022 due to problems in China, a key market for the business, and the fact that the company has been fined for anti-competitive practices by the Competition and Markets Authority (CMA). The company appealed against the CMA decision with the result of this originally expected last year although the outcome is still unknown. However, the result of the appeal should be known in the next few months, whilst most of the issues relating to China and general trading have been resolved.
Alliance Pharma is an international consumer healthcare company…
CONTINUED IN THE FULL NEWSLETTER CLICK TO READ
